Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Sells $62,912.85 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares of the company’s stock, valued at $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Monday, January 6th, Benjamin Landry sold 2,500 shares of Health Catalyst stock. The stock was sold at an average price of $7.52, for a total value of $18,800.00.

Health Catalyst Stock Down 7.5 %

Health Catalyst stock traded down $0.32 during trading hours on Monday, hitting $3.97. 1,010,415 shares of the stock traded hands, compared to its average volume of 898,193. Health Catalyst, Inc. has a one year low of $3.76 and a one year high of $9.24. The firm’s 50-day moving average price is $5.73 and its two-hundred day moving average price is $7.16. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market cap of $278.74 million, a PE ratio of -2.94 and a beta of 1.41.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Stephens cut their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday. Citigroup decreased their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Wells Fargo & Company dropped their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Stifel Nicolaus lowered their price objective on Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research report on Thursday, February 27th. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.27.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Probity Advisors Inc. raised its holdings in Health Catalyst by 33.2% in the fourth quarter. Probity Advisors Inc. now owns 30,692 shares of the company’s stock worth $217,000 after purchasing an additional 7,647 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Health Catalyst in the 4th quarter worth about $248,000. PharVision Advisers LLC bought a new position in shares of Health Catalyst in the 4th quarter worth about $185,000. Two Sigma Advisers LP boosted its stake in Health Catalyst by 72.7% during the fourth quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock worth $210,000 after acquiring an additional 12,500 shares in the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Health Catalyst in the 4th quarter worth approximately $496,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.